(22) Date de dépôt/Filing Date: 2004/06/18
(41) Mise à la disp. pub./Open to Public Insp.: 2004/12/29
(62) Demande originale/Original Application: 2 529 859
(30) Priorités/Priorities: 2003/06/18 (US60/479,182);
2003/06/30 (US60/483,099); 2003/07/10 (US60/485,748);
2003/08/11 (US60/493,793); 2003/10/03 (US60/507,954);
2004/02/19 (US60/545,466)

(51) Cl.Int./Int.Cl. C07D 209/24 (2006.01),
A61K 31/404 (2006.01), A61P 3/06 (2006.01)
(71) Demandeur/Applicant:
TEVA PHARMACEUTICAL INDUSTRIES LTD., IL
(72) Inventeurs/Inventors:
LIFSHITZ-LIRON, REVITAL, IL;
KOLTAI, TAMAS, IL;
ARONHIME, JUDITH, IL;
PERLMAN, NURIT, IL
(74) Agent: HEENAN BLAIKIE LLP

(54) Titre : FORME CRISTALLINE DE SODIUM DE FLUVASTATINE LXXIX, PROCEDES DE PREPARATION,
COMPOSITIONS ET METHODES D'UTILISATION
(54) Title: FLUVASTATIN SODIUM CRYSTAL FORM LXXIX, PROCESSES FOR PREPARING, COMPOSITIONS AND
METHODS OF USING

(57) Abrégé/Abstract:
Provided are polymorphic forms of fluvastatin sodium and processes for their preparation.
WO 2004/113291 A3

Title: FLUVASTATIN SODIUM CRYSTAL FORMS XIV, LXXVIII, LXXX, LXXXI, LXXXII, LXXXIV, LXXXV, LXXXVI, LXXXVII, PROCESSES FOR PREPARING THEM, COMPOSITIONS CONTAINING THEM AND METHODS OF USING THEM

Abstract: Provided are polymorphic forms of fluvastatin sodium and processes for their preparation.


Designated States (unless otherwise indicated, for every kind of regional protection available): ARPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), European (AT, B1, BG, CH, CY, CZ, DE, DK, ES, FI, FR, GB, GR, HU, IT, LU, MC, NL, PL, PT, RO, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TO).
FLUVASTATIN SODIUM CRYSTAL FORM LXXIX, PROCESSES FOR PREPARING, COMPOSITIONS AND METHODS OF USING

PRIORITY


FIELD OF THE INVENTION

The present invention relates to the antihypercholesterolemia and antilipidemia agent fluvastatin and, more particularly, to the solid state properties of its monosodium salt.

BACKGROUND OF THE INVENTION

Complications of cardiovascular disease, such as myocardial infarction, stroke, and peripheral vascular disease account for half of the deaths in the United States. A high level of low density lipoprotein (LDL) in the bloodstream has been linked to the formation of coronary lesions which obstruct the flow of blood and can rupture and promote thrombosis. Goodman and Gilman, The Pharmacological Basis of Therapeutics 879 (9th ed. 1996). Reducing plasma LDL levels has been shown to reduce the risk of clinical events in patients with cardiovascular disease and in patients who are free of cardiovascular disease but who have hypercholesterolemia. Scandinavian Simvastatin Survival Study Group, 1994; Lipid Research Clinics Program, 1984a, 1984b.

Statins drugs are currently the most therapeutically effective drugs available for reducing the level of LDL in the bloodstream of a patient at risk for cardiovascular disease. This class of drugs includes, inter alia, compactin, lovastatin, simvastatin, pravastatin and fluvastatin. The mechanism of action of statin drugs has been elucidated in some detail. They disrupt the synthesis of cholesterol and other sterols in the liver by competitively inhibiting the 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase enzyme ("HMG-CoA reductase"). HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonate, which is the rate determining step in the biosynthesis of cholesterol. Consequently, its inhibition leads to a reduction in the rate of formation of cholesterol in the liver.
[R\textsuperscript{1},S\textsuperscript{1}-(E)]-(\pm)-7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1\textit{H}-indol-2-yl]-3,5-
dihydroxy-6-heptenoic acid is a statin drug. It is known by the trivial name fluvastatin and
has the molecular formula (I):

![Fluvastatin structure]

depicted in free acid form.

Fluvastatin is commercially available under the trade name Lescol\textsuperscript{\textregistered}. Fluvastatin is
supplied as a monosodium salt in capsules containing the equivalent of 20 and 40 mg of
fluvastatin and in extended-release tablets containing the equivalent of 80 mg of
fluvastatin. Fluvastatin and its sodium salt are described in U.S. Patent No. 4,739,073. In
Example 6(a) of the '073 patent, a methyl ester precursor of (\pm) fluvastatin was hydrolyzed
with sodium hydroxide in methanol, which yielded, after evaporation of the methanol,
crude fluvastatin sodium. In Example 6(b), the fluvastatin methyl ester was hydrolyzed
with sodium hydroxide in ethanol. After evaporation of the ethanol, the residue was taken
up in water and lyophilized. The lyophilized product had a melting point range of 194\textdegree C-
197\textdegree C. In Example 8, the sodium salt was prepared by ring opening of fluvastatin lactone
with sodium hydroxide in ethanol as described in Example 6(b). The product of Example
8 produced an infrared spectrum in a KBr pellet with bands at: 3413, 2978, 2936, 1572 and
1216 cm\textsuperscript{-1}.

According to U.S. Patent No. 6,124,340, lyophilization of fluvastatin sodium as
was performed in Examples 6(b) and 8 of the '073 patent yields solid fluvastatin sodium as
a mixture of a crystalline form, designated as Form A, and amorphous material. The '340
patent sets forth the spectroscopic properties of another crystal form of fluvastatin sodium
which is said to have low hygroscopicity and photostability. This other form is called
Form B in the '340 patent. It is characterized by an infrared spectrum with bands at 3343,
2995, 1587, 1536, 1386, 1337, 1042 and 1014 cm\textsuperscript{-1} and by the following powder X-ray
diffraction peak positions and intensities.

<table>
<thead>
<tr>
<th>°2θ</th>
<th>d (Å)</th>
<th>I/I\textsubscript{0} (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.063</td>
<td>21.728</td>
<td>100</td>
</tr>
<tr>
<td>11.056</td>
<td>7.996</td>
<td>2.9</td>
</tr>
<tr>
<td>11.328</td>
<td>7.805</td>
<td>5.5</td>
</tr>
<tr>
<td>12.210</td>
<td>7.243</td>
<td>45.2</td>
</tr>
<tr>
<td>12.965</td>
<td>6.823</td>
<td>34.6</td>
</tr>
<tr>
<td>14.925</td>
<td>5.931</td>
<td>9.3</td>
</tr>
<tr>
<td>20</td>
<td>d (Å)</td>
<td>I/I₀ (%)</td>
</tr>
<tr>
<td>------</td>
<td>---------</td>
<td>----------</td>
</tr>
<tr>
<td>3.965</td>
<td>22.265</td>
<td>100</td>
</tr>
<tr>
<td>7.936</td>
<td>11.131</td>
<td>0.9</td>
</tr>
<tr>
<td>10.554</td>
<td>8.375</td>
<td>1.7</td>
</tr>
<tr>
<td>10.645</td>
<td>8.304</td>
<td>1.5</td>
</tr>
<tr>
<td>11.931</td>
<td>7.412</td>
<td>44.5</td>
</tr>
<tr>
<td>12.215</td>
<td>7.240</td>
<td>14.5</td>
</tr>
<tr>
<td>14.496</td>
<td>6.106</td>
<td>1.1</td>
</tr>
<tr>
<td>14.812</td>
<td>5.976</td>
<td>0.8</td>
</tr>
<tr>
<td>15.916</td>
<td>5.564</td>
<td>0.3</td>
</tr>
<tr>
<td>17.769</td>
<td>4.988</td>
<td>3.2</td>
</tr>
<tr>
<td>18.640</td>
<td>4.756</td>
<td>5.3</td>
</tr>
<tr>
<td>19.856</td>
<td>4.468</td>
<td>5.8</td>
</tr>
<tr>
<td>20.518</td>
<td>4.325</td>
<td>2.9</td>
</tr>
<tr>
<td>20.908</td>
<td>4.245</td>
<td>1.2</td>
</tr>
<tr>
<td>21.389</td>
<td>4.151</td>
<td>1.3</td>
</tr>
<tr>
<td>21.722</td>
<td>4.088</td>
<td>1.1</td>
</tr>
<tr>
<td>22.675</td>
<td>3.918</td>
<td>0.8</td>
</tr>
<tr>
<td>24.089</td>
<td>3.691</td>
<td>1.0</td>
</tr>
</tbody>
</table>

Fluvastatin sodium Form A is said to have the following powder X-ray diffraction peak positions and intensities.
U.S. Patent Application Publication No. 2003/0032666 reports the existence of four crystal forms of fluvastatin monosodium called Forms C, D, E and F. The water content of the forms ranges between 3 and 32%. The new crystal forms of fluvastatin sodium were obtained by storing the samples under atmospheres ranging between 20 and 90% relative humidity.

According to the '666 publication, the PXRD pattern of fluvastatin sodium Form C possesses characteristic peaks at the following d-values and qualitative intensities:

<table>
<thead>
<tr>
<th>d (Å)</th>
<th>Intensity</th>
</tr>
</thead>
<tbody>
<tr>
<td>23.8</td>
<td>(vs)</td>
</tr>
<tr>
<td>11.8</td>
<td>(w)</td>
</tr>
<tr>
<td>7.8</td>
<td>(vs)</td>
</tr>
<tr>
<td>7.6</td>
<td>(vw)</td>
</tr>
<tr>
<td>7.4</td>
<td>(vw)</td>
</tr>
<tr>
<td>6.4</td>
<td>(vw)</td>
</tr>
<tr>
<td>6.1</td>
<td>(vw)</td>
</tr>
<tr>
<td>5.90</td>
<td>(w)</td>
</tr>
<tr>
<td>5.00</td>
<td>(vw)</td>
</tr>
<tr>
<td>4.88</td>
<td>(w)</td>
</tr>
<tr>
<td>4.73</td>
<td>(m)</td>
</tr>
<tr>
<td>4.56</td>
<td>(w)</td>
</tr>
<tr>
<td>4.40</td>
<td>(vw)</td>
</tr>
<tr>
<td>4.12</td>
<td>(vw)</td>
</tr>
<tr>
<td>4.03</td>
<td>(vw)</td>
</tr>
<tr>
<td>3.96</td>
<td>(vw)</td>
</tr>
<tr>
<td>3.50</td>
<td>(vw)</td>
</tr>
<tr>
<td>3.36</td>
<td>(vw)</td>
</tr>
<tr>
<td>2.93</td>
<td>(vw)</td>
</tr>
</tbody>
</table>

wherein (vs) = very strong intensity; (s) = strong intensity; (m) = medium intensity; (w) = weak intensity; and (vw) = very weak intensity.

According to the '666 publication, the PXRD pattern of fluvastatin sodium Form D possesses characteristic peaks at the following d-values and qualitative intensities:
<table>
<thead>
<tr>
<th>$d$ (Å)</th>
<th>Intensity</th>
</tr>
</thead>
<tbody>
<tr>
<td>24.6</td>
<td>(vs)</td>
</tr>
<tr>
<td>12.5</td>
<td>(w)</td>
</tr>
<tr>
<td>8.3</td>
<td>(vs)</td>
</tr>
<tr>
<td>7.4</td>
<td>(vw)</td>
</tr>
<tr>
<td>6.2</td>
<td>(m)</td>
</tr>
<tr>
<td>4.97</td>
<td>(w)</td>
</tr>
<tr>
<td>4.85</td>
<td>(vw)</td>
</tr>
<tr>
<td>4.52</td>
<td>(vw)</td>
</tr>
<tr>
<td>4.40</td>
<td>(vw)</td>
</tr>
<tr>
<td>4.14</td>
<td>(vw)</td>
</tr>
<tr>
<td>3.96</td>
<td>(vw)</td>
</tr>
<tr>
<td>3.41</td>
<td>(vw)</td>
</tr>
<tr>
<td>3.10</td>
<td>(vw)</td>
</tr>
</tbody>
</table>

According to the '666 publication, the PXRD pattern of fluvastatin sodium Form E possesses characteristic peaks at the following $d$-values and qualitative intensities:

<table>
<thead>
<tr>
<th>$d$ (Å)</th>
<th>Intensity</th>
</tr>
</thead>
<tbody>
<tr>
<td>27.6</td>
<td>(m)</td>
</tr>
<tr>
<td>13.9</td>
<td>(vw)</td>
</tr>
<tr>
<td>9.2</td>
<td>(m)</td>
</tr>
<tr>
<td>8.5</td>
<td>(vw)</td>
</tr>
<tr>
<td>8.1</td>
<td>(vw)</td>
</tr>
<tr>
<td>7.4</td>
<td>(vw)</td>
</tr>
<tr>
<td>6.9</td>
<td>($)</td>
</tr>
<tr>
<td>6.1</td>
<td>(vw)</td>
</tr>
<tr>
<td>4.98</td>
<td>(m)</td>
</tr>
<tr>
<td>4.77</td>
<td>(m)</td>
</tr>
<tr>
<td>4.63</td>
<td>(m)</td>
</tr>
<tr>
<td>4.15</td>
<td>(w)</td>
</tr>
<tr>
<td>4.03</td>
<td>(w)</td>
</tr>
<tr>
<td>3.97</td>
<td>(vw)</td>
</tr>
<tr>
<td>3.52</td>
<td>(vw)</td>
</tr>
<tr>
<td>3.33</td>
<td>(vw)</td>
</tr>
<tr>
<td>3.08</td>
<td>(vw)</td>
</tr>
<tr>
<td>2.99</td>
<td>(vw)</td>
</tr>
</tbody>
</table>

According to the '666 publication, the PXRD pattern of fluvastatin sodium Form F possesses characteristic peaks at the following $d$-values and qualitative intensities:
<table>
<thead>
<tr>
<th>$d$ (Å)</th>
<th>Intensity</th>
</tr>
</thead>
<tbody>
<tr>
<td>29.6</td>
<td>(w)</td>
</tr>
<tr>
<td>14.8</td>
<td>(vw)</td>
</tr>
<tr>
<td>9.9</td>
<td>(w)</td>
</tr>
<tr>
<td>8.6</td>
<td>(vw)</td>
</tr>
<tr>
<td>8.3</td>
<td>(vw)</td>
</tr>
<tr>
<td>7.4</td>
<td>(s)</td>
</tr>
<tr>
<td>6.6</td>
<td>(vw)</td>
</tr>
<tr>
<td>6.2</td>
<td>(vw)</td>
</tr>
<tr>
<td>5.93</td>
<td>(w)</td>
</tr>
<tr>
<td>5.03</td>
<td>(m)</td>
</tr>
<tr>
<td>4.94</td>
<td>(m)</td>
</tr>
<tr>
<td>4.35</td>
<td>(vw)</td>
</tr>
<tr>
<td>4.23</td>
<td>(w)</td>
</tr>
<tr>
<td>3.98</td>
<td>(vw)</td>
</tr>
<tr>
<td>3.54</td>
<td>(vw)</td>
</tr>
<tr>
<td>2.98</td>
<td>(vw)</td>
</tr>
</tbody>
</table>

It also deserves mention that International Publication No. WO 02/36563 discloses crystal forms of enantiomerically pure [3R,5S] and [3S,5R] fluvastatin sodium.

The present invention also relates to fluvastatin sodium and the properties that it can exhibit in the condensed phase. The occurrence of different crystal forms (polymorphism) is a property of some molecules and molecular complexes. A single molecule, like the fluvastatin in formula (I) or a salt complex like fluvastatin sodium, may give rise to a variety of solids having distinct physical properties like melting point, X-ray diffraction pattern, infrared absorption fingerprint and NMR spectrum. The crystalline form may give rise to thermal behavior different from that of the amorphous material or another crystalline form. Thermal behavior is measured in the laboratory by such techniques as capillary melting point, thermogravimetric analysis (“TGA”) and differential scanning calorimetry (“DSC”) and can be used to distinguish some polymorphic forms from others. The differences in the physical properties of different crystalline forms result from the orientation and intermolecular interactions of adjacent molecules (complexes) in the bulk solid. Accordingly, polymorphs are distinct solids sharing the same molecular formula yet having distinct advantageous and/or disadvantageous physical properties compared to other forms in the polymorph family. These properties can be influenced by controlling the conditions under which the salt is obtained in solid form.

Exemplary solid state physical properties include the flowability of the milled solid. Flowability affects the ease with which the material is handled during processing into a pharmaceutical product. When particles of the powdered compound do not flow past each other easily, a formulation specialist must take that fact into account in
developing a tablet or capsule formulation, which may necessitate the use of glidants such as colloidal silicon dioxide, talc, starch or tribasic calcium phosphate.

One of the most important physical properties of pharmaceutical polymorphs is their solubility in aqueous solution, particularly their solubility in the gastric juices of a patient. For example, where absorption through the gastrointestinal tract is slow, it is often desirable for a drug that is unstable to conditions in the patient's stomach or intestine to dissolve slowly so that it does not accumulate in a deleterious environment. On the other hand, the method is not advantageous where the effectiveness of a drug correlates with peak bloodstream levels of the drug, as in the case of statin drugs. With a statin drug, provided the drug is rapidly absorbed by the GI system, a more rapidly dissolving form is likely to exhibit increased effectiveness over a comparable amount of a more slowly dissolving form.

It is often the case that the most rapidly dissolving solid state of a compound is amorphous. Amorphous forms are often less stable than crystalline forms because they do not have many of the stabilizing intermolecular interactions that are present in crystalline forms. With an amorphous form, therefore, stabilizing intermolecular interactions do not have to be broken when the compound goes into solution, and so the dissolution rate is not retarded. Although they are more rapidly dissolving than crystalline forms, amorphous forms of a compound can have disadvantages. A compound, when it is in an amorphous state, is frequently more hygroscopic than a crystalline form of the same compound (although exceptions abound, such as when the crystal has wide channels that allow water to enter and leave the crystal in response to changes in moisture density outside the crystal). Water has been implicated in drug stability problems. For instance, the decomposition of aspirin which leads to the characteristic smell of vinegar when an old bottle of aspirin is opened is a hydrolysis reaction catalyzed by water. It is thus prudent when selecting a solid state form of a compound that is to be used as a drug, and possibly stored for a long time between packaging and use, to select a form that has low permeability to water. In the case of fluvastatin monosodium, a crystalline form designated Form B has already been discovered that is purportedly less hygroscopic than the partially crystalline/partially amorphous form of the salt that is obtained by following procedures in U.S. Patent No. 4,739,073.

Although six distinct crystalline forms of racemic fluvastatin sodium have been reported to date, and at least one of them is purported to be less hygroscopic that the solid state form originally reported by the discoverers of the compound, the discovery of yet other crystalline forms of fluvastatin sodium is desirable. The discovery of new crystalline forms and solvates of a pharmaceutically useful compound provides a new opportunity to improve the performance characteristics of a pharmaceutical product by enlarging the
repertoire of materials that a formulation scientist has available for designing. For example, new crystalline forms can be used to design a pharmaceutical dosage form of a drug with low hygroscopicity, a targeted release profile, consistent dosing (enabled by good flow of the tableting composition into the tableting die), or other desired characteristic. New polymorphic forms and solvates of fluvastatin have now been discovered.

**BRIEF DESCRIPTION OF THE FIGURES**

FIG. 1 depicts a powder X-ray diffractogram of fluvastatin sodium Form XIV.

FIG. 2 depicts a DSC thermogram of fluvastatin sodium Form XIV.

FIG. 3 depicts an IR spectrum of fluvastatin sodium Form XIV scanned from 4000 to 400 cm⁻¹, while FIG. 3a expands the 4000-1500 cm⁻¹ region of the spectrum and FIG. 3b expands the 1500-400 cm⁻¹ region of the spectrum.

FIG. 4 depicts a powder X-ray diffractogram of fluvastatin sodium Form XIV, having an additional peak at 12.4±0.2 degrees two-theta.

FIG. 5 depicts a powder X-ray diffractogram of fluvastatin sodium Form LXXIII.

FIG. 6 depicts a powder X-ray diffractogram of fluvastatin sodium Form LXXIX.

FIG. 7 depicts a powder X-ray diffractogram of fluvastatin sodium Form LXXX.

FIG. 8 depicts a powder X-ray diffractogram of fluvastatin sodium Form LXXXVII.

**SUMMARY OF THE INVENTION**

In one aspect, the present invention provides a crystalline form of fluvastatin sodium (Form XIV) characterized by a PXRD pattern with peaks at 3.8, 11.1, 12.9, 17.8 and 21.7 ±0.2 degrees two-theta. In one embodiment, the crystalline form has a peak at 12.4±0.2 degrees two-theta.

In another aspect, the present invention provides a process for preparing the crystalline form of fluvastatin sodium Form XIV comprising: (a) suspending fluvastatin sodium in a mixture of toluene and a C₅ to C₇ saturated hydrocarbon to form a slurry, (b) maintaining the slurry to obtain fluvastatin sodium Form XIV, and (d) separating the fluvastatin sodium Form XIV.

In another aspect, the present invention provides a process for preparing the crystalline fluvastatin sodium Form XIV comprising: (a) dissolving a lower alkyl ester of fluvastatin in a solution containing about one molar equivalent of sodium hydroxide in a solvent system selected from the group consisting of ethanol, mixtures of water and
ethanol, propan-2-ol and mixtures of propan-2-ol and water, mixtures of propan-1-ol and water and mixtures of THF and water, (b) inducing precipitation of the crystalline fluvastatin sodium form by a technique selected from the group consisting of: (i) an anti-solvent selected from the group consisting of acetonitrile, hexanes, dichloromethane and methyl tert-butyl ether with the solution, (ii) cooling the solution, and (iii) both adding an anti-solvent selected from the group consisting of acetonitrile, hexanes, dichloromethane and methyl tert-butyl ether to the solution and cooling the solution, and (c) separating the solvent system and anti-solvent from the crystalline fluvastatin sodium.

In another aspect, the present invention provides a process for preparing crystalline fluvastatin sodium Form XIV, comprising adding MTBE portion wise to a solution of fluvastatin sodium in ethanol as a solvent, wherein the solution is heated before, during or after the addition of MTBE, and recovering the crystalline form.

In another aspect, the present invention provides a process for preparing the crystalline fluvastatin sodium Form XIV comprising: (a) hydrolyzing a lower alkyl ester of fluvastatin in a solution containing about one molar equivalent of sodium hydroxide in a mixture of water and an organic solvent, (b) evaporating the organic solvent from the mixture, (c) evaporating water to obtain a residue, (d) dissolving the residue in a solvent selected from the group consisting of acetonitrile, acetone and isopropyl alcohol, (e) precipitating the crystalline fluvastatin sodium, and (f) recovering the crystalline fluvastatin sodium.

In another aspect, the present invention provides a crystalline form of fluvastatin sodium (Form LXXIII) characterized by a PXRD pattern with peaks at 3.9, 11.5, 17.9, 18.4 and 21.7±0.2 degrees two-theta.

In another aspect, the present invention provides a process for preparing the crystalline fluvastatin sodium Form LXXIII comprising: (a) dissolving fluvastatin sodium in water at elevated temperature, (b) adding an excess of acetonitrile by volume, and (c) recovering the crystalline fluvastatin sodium.

In another aspect, the present invention provides a process for preparing the crystalline fluvastatin sodium Form LXXIII comprising: (a) hydrolyzing a lower alkyl ester of fluvastatin with a sodium base catalyst in a solvent system selected from the group consisting of water and mixtures of water and an organic solvent selected from the group consisting of methanol, ethanol and tetrahydrofuran, (b) contacting the solvent system with
a water immiscible extraction solvent, optionally after evaporation of at least a portion of the organic solvent, (c) evaporating the solvent system to leave a residue, (d) contacting the residue with acetonitrile, and (e) recovering the crystalline fluvastatin sodium.

In another aspect, the present invention provides a process for preparing the crystalline fluvastatin sodium Form LXXIII comprising: (a) dissolving fluvastatin sodium in a mixture of water and propan-2-ol at elevated temperature, (b) reducing the temperature of the mixture, and (c) recovering the crystalline fluvastatin sodium.

In another aspect, the present invention provides a process for preparing the crystalline fluvastatin sodium Form LXXIII comprising storing a crystalline form having a PXRD pattern with peaks at 4.0, 12.8, 19.0, 19.9 and 25.8 ±0.2 degrees two-theta in a mixture of propan-2-ol and water.

In another aspect, the present invention provides a process for preparing the crystallizing fluvastatin Form LXXIII comprising: (a) heating a slurry of fluvastatin sodium Form B in a mixture of propan-2-ol and water, (b) cooling the slurry, (c) storing the slurry for at least about 1 week, and (d) recovering the crystals.

In another aspect, the present invention provides a crystalline form of fluvastatin sodium (Form LXXIX) characterized by a PXRD pattern with peaks at 3.9, 11.7, 15.8, 17.8, 21.8±0.2 degrees two-theta.

In another aspect, the present invention provides a process for preparing the crystalline fluvastatin sodium Form LXXIX comprising: (a) hydrolyzing a lower alkyl ester of fluvastatin with a sodium base catalyst in a mixture of water and ethanol, (b) evaporating a portion of the ethanol and water mixture, (c) contacting the remaining portion of the mixture with a water-immiscible extraction solvent, (d) evaporating the remaining portion of the mixture to leave a residue, (e) contacting the residue with acetonitrile, and (f) recovering the crystalline fluvastatin sodium form.

In another aspect, the present invention provides a crystalline form of fluvastatin sodium (Form LXXX) characterized by a PXRD pattern with peaks at 3.9, 11.8, 17.8, 18.4, 21.7±0.2 degrees two-theta.

In another aspect, the present invention provides a process for preparing the crystalline fluvastatin sodium Form LXXX comprising: (a) hydrolyzing a lower alkyl ester of
fluvasatin with a sodium base catalyst in a mixture of water and ethanol, (b) evaporating a portion of the ethanol and water mixture, (c) contacting the remaining portion of the mixture with a water-immiscible extraction solvent, (d) evaporating the remaining portion of the mixture to leave a residue, (e) contacting the residue with acetonitrile, and (f) recovering the crystalline fluvasatin sodium.

In another aspect, the present invention provides a crystalline form of fluvasatin sodium (Form LXXXVII) characterized by a PXRD pattern with peaks at 3.5, 12.5, 17.7, 19.7, 21.4 ±0.2 degrees two-theta.

In another aspect, the present invention provides a process for preparing the crystalline fluvasatin sodium Form LXXXVII comprising: (a) hydrolyzing a lower alkyl ester of fluvasatin with a sodium base catalyst in a mixture of water and methanol, (b) evaporating methanol from the mixture, (c) contacting the water with a water-immiscible extraction solvent, (d) evaporating the water to leave a residue, (e) contacting the residue with acetonitrile, and (f) recovering the crystalline fluvasatin sodium.

In another aspect, the present invention provides a process for preparing the crystalline fluvasatin sodium Form LXXXVII comprising: (a) hydrolyzing a lower alkyl ester of fluvasatin with a sodium base catalyst in a mixture of water and methanol, (b) evaporating methanol from the mixture, (c) contacting the mixture with acetonitrile, and (d) recovering the crystalline fluvasatin sodium.

In another aspect, the present invention provides a process for preparing crystalline fluvasatin sodium (Form LXXXVII) characterized by a PXRD pattern with peaks at 3.5, 12.5, 17.7, 19.7, 21.4 ±0.2 degrees two-theta comprising heating a mixture of fluvasatin diol tert-butyl ester, methanol, NaOH and water to obtain a solution, evaporating the methanol from the solution followed by adding acetonitrile and optionally water, wherein a solution exists after such addition, and recovering fluvasatin Form LXXXVII as a precipitate.

In another aspect, the present invention provides a process for preparing fluvasatin sodium (Form XIV) characterized by a PXRD pattern with peaks at 3.8, 11.1, 12.9, 17.8 and 21.7 ±0.2 degrees two-theta comprising drying the fluvasatin sodium form LXXXVII.

In another aspect, the present invention provides a process for preparing crystalline fluvasatin sodium (Form XIV) characterized by a PXRD pattern with peaks at 3.8, 11.1,
12.9, 17.8 and 21.7 ±0.2 degrees two-theta comprising heating a mixture of fluvastatia diol tert-butyl ester, methanol, NaOH and water to obtain a solution, evaporating the methanol from the solution followed by adding acetonitrile and optionally water, wherein a solution exists after such addition, recovering fluvastatin sodium as a precipitate and drying the precipitate.

In another aspect, the present invention provides a process for preparing crystalline fluvastatin sodium (Form XIV) characterized by a PXRD pattern with peaks at 3.8, 11.1, 12.9, 17.8 and 21.7 ±0.2 degrees two-theta comprising preparing a solution of fluvastatin sodium in a mixture of water and methanol, evaporating the methanol from the solution while maintaining at least about 1mL of water per gram of tert-butyl ester, adding acetonitrile and optionally water, wherein a solution exists after such addition, recovering fluvastatin sodium as a precipitate and drying the precipitate.

In another aspect, the present invention provides a pharmaceutical composition comprising an effective amount of a fluvastatin sodium form selected from the group consisting of a crystal having a PXRD pattern (Form XIV) 3.8, 11.1, 12.9, 17.8 and 21.7 ±0.2 degrees two-theta, (LXXIII) 3.9, 11.5, 17.9, 18.4 and 21.7±0.2 degrees two-theta, (LXXIX) PXRD pattern with peaks at 3.9, 11.7, 15.8, 17.8, 21.8±0.2 degrees two-theta, (LXXX) PXRD pattern with peaks at 3.9, 11.8, 17.8, 18.4, 21.7±0.2 degrees two-theta, (LXXXVII) PXRD pattern with peaks at 3.5, 12.5, 17.7, 19.7, 21.4 ±0.2 degrees two-theta, and mixtures thereof and a pharmaceutically acceptable excipient. Also provided are pharmaceutical dosage forms from such compositions such as tablets. Also provided are methods of treating a patient suffering from hypercholesterolemia or hyperlipidemia comprising the step of administering to the patient an effective amount of this pharmaceutical composition.

**DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS**

The present invention provides novel crystal forms of \([R^*,S^-\text{(-E)}]\)\((-\text{E})\)\(-\text{E})\)-7-\{3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl\}-3,5-dihydroxy-6-heptenoic acid monosodium (fluvastatin sodium). The novel crystalline forms of fluvastatin sodium have been designated Forms XIV, LXXIII, LXXIX, LXXX and LXXXVII. In so doing we have opted to use Roman numerals as labels for the crystals instead of the Roman alphabetical labels used by others working in the field to label other crystalline forms of fluvastatin sodium.

Whether the two enantiomers of \([R^*,S^-\text{(-E)}]\)\((-\text{E})\)-7-\{3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl\}-3,5-dihydroxy-6-heptenoic acid monosodium (fluvastatin sodium) co-crystallize in a single unit cell or whether they crystallize in separate unit cells that are mirror images of
each other has yet to be determined for all of the new crystals forms. Accordingly, the crystal forms of this invention are considered to include crystals that exhibit substantially the same PXRD patterns as those depicted in the figures whether they are prepared starting from pure or enriched \([R^*,S^*-(E)]-(+\) and \([R^*,S^*-(E)]-(-\) fluvastatin sodium or racemic fluvastatin sodium.

Many of the novel forms can be obtained by crystallization methods and are stable under normal humidity conditions. Those skilled in the art, after reading this disclosure will appreciate that some of the crystallization processes by which the new forms can be made share certain traits. Generally speaking, in those processes fluvastatin sodium is dissolved in a solvent, the selection of which is taught with reference to each particular crystalline form in the sections of this disclosure that follow. While the solution of fluvastatin sodium in the solvent is refluxing, a selected anti-solvent (the selection of which also is taught below) is added to the solution to induce precipitation of fluvastatin sodium in the crystalline form desired. The anti-solvent addition and precipitation can be performed, and preferably are performed, at elevated temperature. Additional precipitation, of course, will occur in many cases during subsequent cooling of the mixture. It will also be seen that in other processes heating of the solvent is not preferred.

By the crystallization processes of this invention, each of the novel crystal forms of fluvastatin sodium is obtained substantially free from other crystal forms, which means less than 5% of any other crystal form as measured by X-ray powder diffraction. The XRD pattern of Form B is significantly different from the XRD pattern of the novel crystal forms. Several XRD peaks of Form B are not overlapping with the XRD peaks of the novel forms. Detection of Form B is possible at 12.2, 16.4 and 22.6±0.2 degrees two theta. Although these processes have been found to yield the novel crystal forms, and yield them in high purity, other processes that produce the crystal forms of this invention in either greater or lesser purity may yet be found.

The yields of the various processes for preparing the new fluvastatin sodium crystal forms vary greatly depending upon the form desired. As those skilled in the art will appreciate, a low yield of the desired crystal form does not necessarily mean that precious unconverted starting material is lost. It, or another crystalline or amorphous form of fluvastatin sodium or fluvastatin free acid or lactone can be recovered from the separated solvent or diluent, such as by evaporating the separated diluent or solvent used in the process to leave a residue containing fluvastatin.

Some of the new forms of fluvastatin sodium are hydrated. The level of water in fluvastatin sodium is measured by Karl Fisher using methods known in the art. Some of the new crystal forms of fluvastatin sodium contain residual solvent in addition to water, which is seen by the fact that the TGA weight loss value is significantly larger than the
Karl Fisher value. Some of the solvated crystal forms contain only small quantities of residual solvent. In this latter group, fluvastatin sodium can be found in the following hydrated states: hemihydrate (water content about 2%); monohydrate (water content about 3-4%); sesquihydrate (water content about 5-6%); dihydrate (water content about 7-8%); hemipentahydrate (water content about 9-10%); trihydrate (water content about 11-13%); tetrahydrate (water content about 14-16%); pentahydrate (water content 17-18%); hexahydrate (water content about 19-20%); 8-hydrate (water content about 25%); 9-hydrate (water content about 27-28%).

Fluvastatin is a known compound that can be purchased from commercial sources or synthesized by known processes such as the process disclosed in U.S. Patent No. 4,739,073, which is incorporated herein by reference in its entirety. In particular, U.S. Patent No. 4,739,073 is incorporated herein for its disclosure of how to prepare fluvastatin and fluvastatin sodium. In the processes of this invention that use fluvastatin sodium as a starting material, fluvastatin sodium Form B is the preferred starting material unless otherwise indicated.

As used in this disclosure, the term "elevated temperature" means a temperature above ambient temperature or above about 25°C. Preferred elevated temperatures are 50°C and above and especially preferred elevated temperatures, when used in reference to contacting with particular liquids, are the boiling points of such liquids.

The term "lower alkyl" means a C₁ to C₄ alkyl group.

The terms "suspend" or "slurry" refer to a heterogeneous mixture where complete dissolution does not occur.

The term "anti-solvent" means a liquid that, when added to a solution of fluvastatin sodium in a solvent, induces precipitation of fluvastatin sodium. Precipitation of fluvastatin sodium is induced by the anti-solvent when addition of the anti-solvent causes fluvastatin sodium to precipitate from the solution more rapidly or to a greater extent than fluvastatin sodium precipitates from a solution containing an equal concentration of fluvastatin in the same solvent when the solution is maintained under the same conditions for the same period of time but without adding the anti-solvent. Precipitation can be perceived visually as a clouding of the solution or formation of distinct particles of fluvastatin sodium suspended in or on the surface of the solution or collected on the walls or at the bottom of the vessel containing the solution.

The particle size distribution (PSD) of the forms can be studied by several techniques. The most common PSD techniques include sieving, sedimentation, electozone sensing (Coulter Counter), microscopy and Low angle Laser Light Scattering (LLALLS). The novel crystal forms have a maximal particle size of less than about 400μm, more preferably less than about 300μm, more preferably less than about 200μm, more preferably
less than 100µm, more preferably less than 50µm. The maximal size can be seen under an optical microscope.

**Fluvastatin Sodium Crystal Form XIV**

Fluvastatin sodium Form XIV produces a PXRD diffractogram with characteristic peaks at 3.8, 11.1, 12.9, 17.8 and 21.7±0.2 degrees two-theta and other peaks at 9.2, 14.8, 15.7, 18.3, 20.3, 25.5 and 26.9±0.2 degrees two-theta (FIG. 1). Some crystals have all the peaks associated with Form XIV and exhibit many of characteristics of Form XIV, but have an additional peak at 12.4 ±0.2 degrees two-theta (FIG. 4). Fluvastatin sodium Form XIV produced the DSC thermogram shown in FIG. 2, in which two main endothermic peaks can be seen below 90°C and at about 110 °C. The water content of the sample is about 7.1 wt. %. The loss on drying by TGA is 7.5 wt. %. Fluvastatin sodium Form XIV was stable after exposure to relative humidities between 0-100% RH for 8 days and equilibrated at water contents between 6-17%. Fluvastatin Form XIV is in dihydrate, trihydrate, tetrahydrate, and pentahydrate forms. The IR spectrum of fluvastatin sodium Form XIV is shown in FIGs. 3, 3a and 3b.

Form XIV has the appearance of a white to pale yellow powder. Stability studies have shown that its appearance does not change after storage at 40°C for three months.

The present invention further provides a fluvastatin sodium Form XIV, of which no more than about 5% transforms into Form B upon storage at a temperature of 25, 40 and 55°C, for at least 3 months (see table 1).

**Table 1**

**Stability study of Form XIV**

Polymorph content by X-Ray Powder Diffraction analysis

<table>
<thead>
<tr>
<th>Time interval</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>t=0</td>
<td>XIV</td>
</tr>
<tr>
<td>1M</td>
<td>XIV</td>
</tr>
<tr>
<td>2M</td>
<td>XIV</td>
</tr>
<tr>
<td>3M</td>
<td>XIV</td>
</tr>
</tbody>
</table>

Fluvastatin sodium Form XIV can be prepared by suspending fluvastatin sodium in a mixture of toluene and a C₅ to C₇ straight or branched saturated hydrocarbon such as hexanes to obtain a slurry, *i.e.*, a heterogeneous mixture, for a period of time necessary to
effect the conversion and then separating Form XIV from the mixture. Form XIV also can be prepared by storing Form VII under 100% RH for 11 days.

Fluvastatin sodium Form XIV also can be prepared directly from a straight or branched lower alkyl ester of fluvastatin. The starting material is dissolved in a solution containing about 1 molar equivalent of sodium hydroxide in a solvent system selected from the group consisting of ethanol, mixtures of water and ethanol, propan-2-ol and mixtures of water and propan-2-ol, mixtures of THF and water and mixtures of propan-1-ol and water. Preferred mixtures contain about 8-9% water and 91-92% organic solvent, except for THF-water mixtures for which the mixture preferably contains about 5% water. The starting material preferably is dissolved at elevated temperature, e.g. the reflux temperature of the solvent system. At elevated temperature, an anti-solvent selected from the group consisting of acetonitrile, hexanes, dichloromethane and MTBE is added at elevated temperature to the solution to induce precipitation of Form XIV. Alternatively, the anti-solvent may be omitted and precipitation induced by cooling from some solvent systems, such as propan-2-ol:water mixtures. After allowing the resulting mixture to cool, Form XIV can be separated from the solvent system and anti-solvent by conventional techniques such as filtering, decanting, centrifuging and the like, preferably filtering under an inert atmosphere like nitrogen. The separated Form XIV may be dried. A suitable drying condition is 50°C under vacuum.

According to an alternative process, Form XIV is prepared from a straight or branched lower alkyl ester of fluvastatin by hydrolyzing the starting material in a solution containing about 1 molar equivalent of sodium hydroxide in a solvent system containing water and an organic solvent selected from the group consisting of methanol, ethanol and THF. After hydrolysis, the organic solvent is evaporated and, optionally, more water is added, the aqueous solution may be extracted with a water immiscible solvent such as ethyl acetate, acetone or isopropyl alcohol. Then the water is evaporated and the residue is taken up in acetonitrile and allowed to recrystallize from the acetonitrile to yield Form LXXIX. If the amount water remaining after evaporation step is too low, then Form B is obtained. Preferably after evaporation amount of water remaining is at least about 1 mL per gram of fluvastatin sodium. Form LXXIX can be separated from the acetonitrile by conventional techniques such as filtering, decanting, centrifuging and the like, preferably filtering under an inert atmosphere like nitrogen. The separated Form LXXIX may then be dried to obtain Form XIV. A suitable drying condition is about 30°C to about 60°C, such as about 40°C or about 50°C, more preferably under vacuum. A preferred vacuum pressure is below about 100 mmHg, more preferably below about 50 mmHg.

Form XIV may also be prepared by adding portion wise MTBE, hexane, acetonitrile or dichloromethane, to a solution of fluvastatin sodium in ethanol, propan-2-ol or
tetrahydrofuran as a solvent, wherein the solution is heated before, during or after of the addition, and recovering the crystalline form. An example of portion wise addition is dropwise. In one embodiment, the anti-solvent is added dropwise, followed by heating, followed by cooling and stirring to recover the crystalline form. The solvent may contain water, preferably less than about 10% by volume. In another embodiment, Form XVI is prepared by combining a solution of fluvastatin sodium in water with iso-propyl alcohol, ethyl acetate, acetonitrile or acetone. After addition, the reaction mixture may be stirred and the crystals recovered by conventional manner.

Form XIV can be prepared in high purity by the foregoing processes. In addition to being polymorphically pure, crystallization of fluvastatin sodium into Form XIV is especially effective at removing impurities. For instance, HPLC of samples of Form XIV shows that it typically contains less than 0.5% of hydroxy epimers of fluvastatin and less than 1% total impurities. HPLC was performed according to the method of Pharmacopeial Previews, 1999, 24, 8420.

Fluvastatin Sodium Crystal Form LXXIII

Fluvastatin sodium Form LXXIII produces a PXRD pattern (FIG. 5) having characteristic peaks at 3.9, 11.5, 17.9, 18.4 and 21.7±0.2 degrees two-theta and other peaks at 9.5, 13.4, 19.2 and 25.6±0.2 degrees two-theta. The water content of the sample is about 6 wt. %. The loss on drying by TGA is about 6 wt. %.

Form LXXIII can be prepared from fluvastatin sodium Form characterized by a powder XRD pattern of 3.7, 4.7, 5.7, 10.9, 12.2 and 19.9±0.2 degrees two-theta (denominated Form VI) by dissolving Form VI in refluxing water and then adding a ten fold excess of acetonitrile (preferably more than about a five fold excess) to the water to induce precipitation of fluvastatin sodium in Form LXXIII. After cooling to ambient temperature, Form LXXIII can be separated from the acetonitrile and water by conventional means such as by filtering, decanting, centrifuging and the like. Preferably, the acetonitrile and water are separated by vacuum filtration under an inert gas like nitrogen. After optional washing, for example with acetonitrile, the crystals can be dried.

A suitable condition for drying the separated product is 50°C under vacuum.

Form LXXIII also can be prepared directly from a lower alkyl ester of fluvastatin as further described in the Examples below.

Further, Form LXXIII can be prepared by dissolving fluvastatin sodium Form XIV in a refluxing 10:1 mixture of propan-2-ol and water. After dissolution is complete, the solution is cooled or allowed to cool and maintained at ambient temperature for a sufficient period of time in order for fluvastatin sodium to precipitate as Form LXXIII. The dissolution results in a loss of crystal structure. Thereafter Form LXXIII can be
separated from the propan-2-ol and water by conventional means such as filtering, decanting, centrifuging and the like. Preferably, the propan-2-ol and water are separated by vacuum filtration under an inert gas like nitrogen. After optional washing, for example with propan-2-ol, the crystals can be dried. A suitable condition for drying the separated product is 50°C under vacuum.

Form LXXIII may also be prepared by a process that includes storing Form LXXIV in a mixture of propan-2-ol and water. Such storing is preferably carried out for at least about one week, more preferably at least about 1 month, and most preferably about 2 months. Form LXXIII may be prepared in such way without isolation of Form LXXIV.

Form example, fluvastatin sodium Form B would be heated in a mixture of propan-2-ol and water without complete dissolution, then cooled and then stored in the mother liquor for at least about 1 week. Form LXXIII may then be recovered from the mother liquor.

Fluvastatin Sodium Crystal Form LXXIX

Fluvastatin sodium Form LXXIX produces a PXRD pattern (FIG. 6) having characteristic peaks at 3.9, 11.7, 15.8, 17.8, 21.8±0.2 degrees two-theta and other peaks at 13.0, 18.3, 19.5, 22.6±0.2 degrees two-theta. Form LXXIX does not transform into Form B by more than 5% upon storage under exposure to relative humidities of about 0 to about 100% for at least 8 days and has a water content of about 3 to about 19%. The loss on drying by TGA is about 6 wt. %. Form LXXIX may be in a monohydrate, a sesquihydrate, a dihydrate, a trihydrate, a tetrahydrate, a pentahydrate or a hexahydrate form.

Form LXXIX can be prepared directly from a lower alkyl ester of fluvastatin such as fluvastatin tert-butyl ester. The starting material is hydrolyzed with a sodium base in a mixture of water and an organic solvent selected from the group consisting of ethanol, methanol and THF. The mixture is partially concentrated and then additional water is added to the concentrated mixture. Then, the reaction mixture is extracted with ethyl acetate or MTBE. The aqueous phase is concentrated. The residue is then contacted with acetonitrile for several hours. After conventional separation of the acetonitrile, the fluvastatin sodium is in Form LXXIX. After optional washing, for example with acetonitrile, the crystals can be dried. A suitable condition for drying the separated product is 50°C under vacuum.

Fluvastatin Sodium Crystal Form LXXX

Fluvastatin sodium Form LXXX produces a PXRD pattern (FIG. 7) having characteristic peaks at 3.9, 11.8, 17.8, 18.4, 21.7±0.2 degrees two-theta and other peaks at 10.8, 12.5, 19.3, 25.5±0.2 degrees two-theta.
Form LXXX can be prepared directly from a lower alkyl ester of fluvastatin such as fluvastatin tert-butyl ester. The starting material is hydrolyzed with a sodium base in a mixture of ethanol and water. The mixture is partially concentrated and then additional water is added to the concentrated mixture. Then, the reaction mixture is extracted with ethyl acetate. The aqueous phase is concentrated. The residue is then contacted with acetonitrile for several hours. After conventional separation of the acetonitrile, the fluvastatin sodium is in Form LXXX. After optional washing, for example with acetonitrile, the crystals can be dried. A suitable condition for drying the separated product is 50°C under vacuum.

Fluvastatin Sodium Crystal Form LXXXVII

Fluvastatin sodium Form LXXXVII produces a PXRD pattern (FIG. 8) having characteristic peaks at 3.5, 12.5, 17.7, 19.7, 21.4 ±0.2 degrees two-theta and other peaks at 7.1, 10.7, 18.3, 19.1, 25.5±0.2 degrees two-theta.

Form LXXXVII can be prepared directly from a lower alkyl ester of fluvastatin such as fluvastatin tert-butyl ester. The starting material is hydrolyzed with a sodium base in a mixture of methanol and water at elevated temperature. After the reaction, the methanol is removed, such as by evaporation. Then, the reaction mixture is optionally extracted with MTBE. In one embodiment, the aqueous phase is concentrated and then the residue is contacted with acetonitrile for several hours. In another embodiment, acetonitrile is added after removal of the methanol. After conventional separation of the acetonitrile, the fluvastatin sodium is in Form LXXXVII. After optional washing, for example with acetonitrile, the crystals can be dried. A suitable condition for drying the separated product is 50°C under vacuum.

The crystalline forms of Fluvastatin sodium provided by the present invention may have high hygroscopicity or low hygroscopicity.

Pharmaceutical Compositions and Dosage Forms Containing And Methods of Medical Treatment Using The Novel Fluvastatin Sodium Forms

Fluvastatin exerts an antihypercholesterolemia and antihyperlipidemia effect in mammals, especially humans. Accordingly, fluvastatin sodium Forms XIV, LXXXIII, LXXIX, LXXX, LXXXVII and mixtures thereof with each other as well as with other crystalline forms of fluvastatin sodium are useful for delivering fluvastatin to the gastrointestinal tract, bloodstream and liver of humans and other mammals suffering from or at risk of atherosclerosis. In particular, they are useful as active ingredients in pharmaceutical compositions and dosage forms. For this purpose, they may be formulated into a variety of compositions and dosage forms for administration to humans and animals.
Pharmaceutical compositions of the present invention contain fluvastatin sodium Form XIV, LXXIII, LXXIX, LXXX, LXXXXVII or mixtures thereof with each other or other crystalline forms of fluvastatin sodium, optionally in mixtures with one or more other active ingredient(s). In addition to the active ingredient(s), the pharmaceutical compositions of the present invention may contain one or more excipients. Excipients are added to the composition for a variety of purposes.

Diluents increase the bulk of a solid pharmaceutical composition and may make a pharmaceutical dosage form containing the composition easier for the patient and care giver to handle. Diluents for solid compositions include, for example, microcrystalline cellulose (e.g. Avicel®), microfine cellulose, lactose, starch, pregelatinized starch, calcium carbonate, calcium sulfate, sugar, dextrates, dextrin, dextrose, dibasic calcium phosphate dihydrate, tribasic calcium phosphate, kaolin, magnesium carbonate, magnesium oxide, maltodextrin, mannitol, polymethacrylates (e.g. Eudragit®), potassium chloride, powdered cellulose, sodium chloride, sorbitol and talc.

Solid pharmaceutical compositions that are compacted into a dosage form like a tablet may include excipients whose functions include helping to bind the active ingredient and other excipients together after compression. Binders for solid pharmaceutical compositions include acacia, alginic acid, carborer (e.g. carbopol), carboxymethylcellulose sodium, dextrin, ethyl cellulose, gelatin, guar gum, hydrogenated vegetable oil, hydroxyethyl cellulose, hydroxypropyl cellulose (e.g. Klucel®), hydroxypropyl methyl cellulose (e.g. Methocel®), liquid glucose, magnesium aluminum silicate, maltodextrin, methylcellulose, polymethacrylates, povidone (e.g. Kollidon®, Plasdone®), pregelatinized starch, sodium alginate and starch.

The dissolution rate of a compacted solid pharmaceutical composition in the patient’s stomach may be increased by the addition of a disintegrant to the composition. Disintegrants include alginic acid, carboxymethylcellulose calcium, carboxymethylcellulose sodium (e.g. Ac-Di-Sol®, Primellose®), colloidal silicon dioxide, croscarmellose sodium, crospovidone (e.g. Kollidon®, Polyplasdone®), guar gum, magnesium aluminum silicate, methyl cellulose, microcrystalline cellulose, polacrilin potassium, powdered cellulose, pregelatinized starch, sodium alginate, sodium starch glycolate (e.g. Explotab®) and starch.

Glidants can be added to improve the flow properties of non-compacted solid composition and improve the accuracy of dosing. Excipients that may function as glidants include colloidal silicon dioxide, magnesium trisilicate, powdered cellulose, starch, talc and tribasic calcium phosphate.

When a dosage form such as a tablet is made by compaction of a powdered composition, the composition is subjected to pressure from a punch and die. Some
excipients and active ingredients have a tendency to adhere to the surfaces of the punch and die, which can cause the product to have pitting and other surface irregularities. A lubricant can be added to the composition to reduce adhesion and ease release of the product from the die. Lubricants include magnesium stearate, calcium stearate, glyceryl monostearate, glyceryl palmitostearate, hydrogenated castor oil, hydrogenated vegetable oil, mineral oil, polyethylene glycol, sodium benzoate, sodium lauryl sulfate, sodium stearyl fumarate, stearic acid, talc and zinc stearate.

Flavoring agents and flavor enhancers make the dosage form more palatable to the patient. Common flavoring agents and flavor enhancers for pharmaceutical products that may be included in the composition of the present invention include maltol, vanillin, ethyl vanillin, menthol, citric acid, fumaric acid, ethyl maltol, and tartaric acid.

Solid and liquid compositions may also be dyed using any pharmaceutically acceptable colorant to improve their appearance and/or facilitate patient identification of the product and unit dosage level.

In liquid pharmaceutical compositions of the present invention, fluvasatin sodium Form XIV, LXXIII, LXXIX, LXXX, LXXXVII and any other solid excipients are dissolved or suspended in a liquid carrier such as water, vegetable oil, alcohol, polyethylene glycol, propylene glycol or glycerin.

Liquid pharmaceutical compositions may contain emulsifying agents to disperse uniformly throughout the composition an active ingredient or other excipient that is not soluble in the liquid carrier. Emulsifying agents that may be useful in liquid compositions of the present invention include, for example, gelatin, egg yolk, casein, cholesterol, acacia, tragacanth, chondrus, pectin, methyl cellulose, carbomer, cetostearyl alcohol and cetyl alcohol.

Liquid pharmaceutical compositions of the present invention may also contain a viscosity enhancing agent to improve the mouth-feel of the product and/or coat the lining of the gastrointestinal tract. Such agents include acacia, alginic acid bentonite, carbomer, carboxymethylcellulose calcium or sodium, cetostearyl alcohol, methyl cellulose, ethylcellulose, gelatin guar gum, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, maltodextrin, polyvinyl alcohol, povidone, propylene carbonate, propylene glycol alginate, sodium alginate, sodium starch glycolate, starch tragacanth and xanthan gum.

Sweetening agents such as sorbitol, saccharin, sodium saccharin, sucrose, aspartame, fructose, mannitol and invert sugar may be added to improve the taste.

Preservatives and chelating agents such as alcohol, sodium benzoate, butylated hydroxy toluene, butylated hydroxyanisole and ethylenediamine tetraacetic acid may be added at levels safe for ingestion to improve storage stability.
A liquid composition according to the present invention may also contain a buffer such as glycine, lactic acid, citric acid or acetic acid, sodium glycinate, sodium lactate, sodium citrate or sodium acetate.

Selection of excipients and the amounts to use may be readily determined by the formulation scientist based upon experience and consideration of standard procedures and reference works in the field.

The solid compositions of the present invention include powders, granulates, aggregates and compacted compositions. The dosage forms include dosage forms suitable for oral, buccal, rectal, parenteral (including subcutaneous, intramuscular, and intravenous), inhalant and opthalmic administration. Although the most suitable route in any given case will depend on the nature and severity of the condition being treated, the most preferred route of the present invention is oral. The dosages may be conveniently presented in unit dosage form and prepared by any of the methods well-known in the pharmaceutical arts.

Dosage forms include solid dosage forms like tablets, powders, capsules, suppositories, sachets, troches and lozenges as well as liquid syrups, suspensions and elixirs.

An especially preferred dosage form of the present invention is a capsule containing the composition, preferably a powdered or granulated solid composition of the invention, within either a hard or soft shell. The shell may be made from gelatin and optionally contain a plasticizer such as glycerin and sorbitol, and an opacifying agent or colorant. An especially preferred capsule filling contains, in addition to one or more of the fluvastatin sodium crystalline forms of this invention, the excipients magnesium stearate, microcrystalline cellulose, pregelatinized starch, sodium lauryl sulfate and talc.

Another especially preferred dosage form of this invention is a compressed tablet that contains, in addition to one or more of the fluvastatin sodium crystalline forms of this invention, the excipients microcrystalline cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, potassium bicarbonate, povidone, magnesium stearate, iron oxide yellow, titanium dioxide and polyethylene glycol 8000.

The active ingredient and excipients may be formulated into compositions and dosage forms according to methods known in the art.

A composition for tableting or capsule filing may be prepared by wet granulation. In wet granulation some or all of the active ingredients and excipients in powder form are blended and then further mixed in the presence of a liquid, typically water, that causes the powders to clump up into granules. The granulate is screened and/or milled, dried and then screened and/or milled to the desired particle size. The granulate may then be
tableted or other excipients may be added prior to tableting such as a glidant and or lubricant.

A tableting composition may be prepared conventionally by dry blending. For instance, the blended composition of the actives and excipients may be compacted into a slug or a sheet and then comminuted into compacted granules. The compacted granules may be compressed subsequently into a tablet.

As an alternative to dry granulation, a blended composition may be compressed directly into a compacted dosage form using direct compression techniques. Direct compression produces a more uniform tablet without granules. Excipients that are particularly well suited to direct compression tableting include microcrystalline cellulose, spray dried lactose, dicalcium phosphate dihydrate and colloidal silica. The proper use of these and other excipients in direct compression tableting is known to those in the art with experience and skill in the particular formulation challenges of direct compression tableting.

A capsule filling of the present invention may comprise any of the aforementioned blends and granulates that were described with reference to tableting, only they are not subjected to a final tableting step.

Capsules, tablets and lozenges and other unit dosage forms preferably contain a dosage equivalent to from about 10 to about 100 mg fluvasatin. Preferably the dosage is equivalent to from about 20 to about 80 mg of fluvasatin. More particularly, immediate or uncontrolled release dosage forms preferably contain the equivalent of from about 20 to about 40 mg of fluvasatin and extended release dosage forms preferably contain the equivalent of from about 60 to about 100 mg of fluvasatin, more preferably about 80 mg of fluvasatin.

Having thus described the present invention with reference to certain preferred embodiments, the processes for producing Fluvasatin sodium Forms XIV, LXXIII, LXXIX, LXXX and LXXXVII of the present invention and techniques suitable for identifying them are further illustrated by the examples which follow. These examples are provided for illustrative purposes only and are not intended to limit the invention in any way.

EXAMPLES
General

Powder X-ray diffraction data were obtained using methods known in the art on a SCINTAG powder X-ray diffractometer model XTRA equipped with a solid state detector. Copper radiation of 1.5418 Å was used. A round aluminum sample holder with zero background was used. Detection limit: about 5% Form B.
DSC analysis was done on a Mettler 821 Star e. The weight of the samples was about 5 mg; the samples were scanned at a rate of 10°C/min from 30°C to 200°C. The oven was constantly purged with nitrogen gas at a flow rate of 40 ml/min. Standard 40 μl aluminum crucibles covered by lids with 3 holes were used.

TGA analysis was done using a Mettler M3 meter. The weight of the samples was about 10 mg; the samples were scanned at a rate of 10°C/min from 25°C to 200°C. The oven was constantly purged with nitrogen gas at a flow rate of 40 ml/min. Standard 70 μl alumina crucibles covered by lids with 1 hole were used.

IR analysis was done using a Perkin Elmer "Spectrum One" FT-IR spectrometer in DRIFT mode. The samples in the 4000-400 cm⁻¹ interval were scanned 16 times with 4.0 cm⁻¹ resolution.

The water content of fluvasatin sodium is measured by the methods known in the art like Karl Fisher or thermogravimetric analysis.

Those skilled in the art will recognize the abbreviations used in the disclosure, as they are in widespread use in the fields of medicinal and organic chemistry. The abbreviations used include the following:

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACN</td>
<td>acetonitrile</td>
</tr>
<tr>
<td>DMF</td>
<td>N,N-dimethyl formamide</td>
</tr>
<tr>
<td>DMSO</td>
<td>dimethyl sulfoxide</td>
</tr>
<tr>
<td>EtOH</td>
<td>ethanol</td>
</tr>
<tr>
<td>Et₂O</td>
<td>diethyl ether</td>
</tr>
<tr>
<td>EtOAc</td>
<td>ethyl acetate</td>
</tr>
<tr>
<td>IPA</td>
<td>isopropyl alcohol</td>
</tr>
<tr>
<td>MeOH</td>
<td>methanol</td>
</tr>
<tr>
<td>MTBE</td>
<td>methyl tert-butyl ether</td>
</tr>
<tr>
<td>MEK</td>
<td>methyl ethyl ketone</td>
</tr>
<tr>
<td>THF</td>
<td>tetrahydrofuran</td>
</tr>
</tbody>
</table>

**Preparative**

All the preparations described below were carried out on fluvasatin sodium Form B except where indicated otherwise.

**Preparation of Fluvasatin Sodium Crystal Form XIV**

**Example 1**

Fluvasatin sodium (3.0 g) was suspended in a mixture of toluene (60 ml) and hexanes (60 ml) at reflux temperature for 19 h. Then, the mixture was cooled to room
temperature. The product was isolated by filtration under nitrogen, washed with hexanes (2x10 ml) and dried at 50°C in a vacuum oven for 22 h to obtain 1.2 g (39%) of fluvastatin sodium crystal Form XIV.

Example 2

Fluvastatin methyl ester (3.0 g) was added to a solution of NaOH (1 eq.) in water (0.75 ml) and ethanol (7.5 ml). The mixture was heated to reflux and stirred until the starting material was no longer detectable by HPLC. Then, 58 ml of MTBE was dripped into the solution over 1.5 h. Turbidity appeared in the solution. The mixture was cooled slowly to room temperature and stirred overnight. The product was isolated by filtration under nitrogen, washed with MTBE (50 ml) and dried at 50°C in a vacuum oven for 24 h to obtain 2.21 g (72.3%) of fluvastatin sodium Form XIV.

Example 3

Fluvastatin methyl ester (2.0 g) was added to a solution of NaOH (1 eq.) in ethanol (15 ml). The mixture was stirred at about 70°C for 1.75 h, after which the starting material was no longer detectable by HPLC. Then, 40 ml of MTBE was dripped into the solution. The mixture was cooled slowly to room temperature and stirred overnight. The product could not be filtrated so another 100 ml of MTBE was added and the mixture was stirred over the weekend. The product was isolated by filtration under nitrogen and dried at 50°C in a vacuum oven for 24 h to obtain 1.45 g (71.2%) of fluvastatin sodium Form XIV.

Example 4

Fluvastatin methyl ester (2.0 g) was added to a solution of NaOH (1 eq.) in propan-2-ol (15 ml). The mixture was stirred at about 70°C for 2 h, after which the starting material was no longer detectable by HPLC. Then, acetonitrile (40 ml) was dripped into the mixture. The mixture was cooled slowly to room temperature and stirred overnight. The product was isolated by filtration under nitrogen, washed with acetonitrile (50 ml) and dried at 50°C in a vacuum oven for 24 h to obtain 1.54 g (75.5%) of fluvastatin sodium Form XIV.

Example 5

Fluvastatin methyl ester (3.0 g) was added to a solution of NaOH (1 eq.) in water (0.75 ml) and propan-2-ol (7.5 ml). The mixture was heated to reflux and 1 ml of propan-2-ol was added. After 2 h, the mixture was cooled to room temperature and stirred for 2 h. MTBE (60 ml) was dripped into the solution over 20 min and the resulting mixture was stirred for another 1.5 h. The product was isolated by filtration under nitrogen, washed with MTBE and dried at 50°C in a vacuum oven for 24 h to obtain 1.9 g (62%) of fluvastatin sodium Form XIV.
Example 6

Fluvastatin sodium (3.0 g) was dissolved in a mixture of propan-2-ol (50 ml) and water (5 ml) at reflux temperature. MTBE (50 ml) was added dropwise and the mixture was stirred at reflux temperature for 1/2 h. Then, the mixture was cooled to room temperature and stirred at this temperature for 16 h. Another portion of MTBE (50 ml) was added to obtain further precipitation. After 5 h, the product was isolated by filtration under nitrogen, washed with MTBE (2x10 ml) and dried at 50°C in a vacuum oven for 24 h to obtain fluvastatin sodium Form XIV (1.4 g, 48%).

Example 7

Fluvastatin sodium (30.0 g) was dissolved in a mixture of propan-2-ol (500 ml) and water (50 ml) at reflux temperature. The obtained solution was stirred at reflux temperature for 1.5 h. Then, the mixture was cooled to room temperature and stirred at this temperature for 16 h. The product was isolated by filtration under nitrogen, washed with propan-2-ol (2x100 ml) and dried at 50°C in a vacuum oven for 23 h to obtain fluvastatin sodium Form XIV (14.8 g, 49%).

Example 8

Fluvastatin sodium (3.0 g) was dissolved in a mixture of propan-1-ol (30 ml) and water (3 ml) at reflux temperature. MTBE (60 ml) was added dropwise and the mixture was stirred at reflux temperature for 1 h. Then, the mixture was cooled to room temperature and stirred at this temperature for 3 h. The product was isolated by filtration under nitrogen, washed with MTBE (2x15 ml) and dried at 50°C in a vacuum oven for 20 h to obtain fluvastatin sodium Form XIV (2.2 g, 74%).

Example 9

Fluvastatin sodium (4.0 g) was dissolved in a mixture of THF (20 ml) and water (1 ml) at reflux temperature. MTBE (40 ml) was added dropwise and the mixture was stirred at reflux temperature for 1 h. Then, the mixture was cooled to room temperature and stirred at this temperature for 4.5 h. The product was isolated by filtration under nitrogen, washed with MTBE (2x20 ml) and dried at 50°C in a vacuum oven for 24 h to obtain fluvastatin sodium Form XIV (1.9 g, 47%).

Example 10

Fluvastatin sodium (4.0 g) was dissolved in a mixture of THF (20 ml) and water (1 ml) at reflux temperature. Dichloromethane (40 ml) was added dropwise and the mixture was stirred at reflux temperature for 40 minutes. Then, the mixture was cooled to room temperature and stirred at this temperature for 24 h. The product was isolated by filtration under nitrogen, washed with dichloromethane (2x20 ml) and dried at 50°C in a vacuum oven for 24 h to obtain fluvastatin sodium Form XIV (3.8 g, 94%).
Example 11

Fluvastatin sodium (4.0 g) was dissolved in a mixture of THF (20 ml) and water (1 ml) at reflux temperature. Hexanes (40 ml) was added dropwise and the mixture was stirred at reflux temperature for 40 minutes. Then, the mixture was cooled to room temperature and stirred at this temperature for 4 h. The product was isolated by filtration under nitrogen, washed with Dichloromethane (2x20 ml) and dried at 50°C in a vacuum oven for 24 h to obtain fluvastatin sodium Form XIV (2.6 g, 66%).

Example 12

A 250 ml round bottom flask was loaded with fluvastatin (20.0g, 47mmole), water (60ml) and ethanol (100ml) and NaOH (1.94g). The mixture became clear and was stirred until the raw material wasn't observed by HPLC. The solution was filtered and the EtOH was distilled. Water (157ml) was added to the slurry mixture, which was extracted with EtOAc (2x100ml). The clear solution was divided to 6 parts.

Example 13

A solution of fluvastatin sodium that was prepared as described in Example 12 (42ml) was concentrated until the water volume was ca. 1.5 ml then IPA (68 ml) was added and the mixture was stirred at room temperature for 18 h. The product was isolated by filtration under nitrogen, washed with IPA (20ml) and dried at 40°C in a vacuum oven for 24 h to obtain 1.12 g (ca. 33%) of fluvastatin sodium crystal Form XIV.

Example 14

A solution of fluvastatin sodium that was prepared as described in Example 12 (42ml) was concentrated until the water volume was ca. 1.8 ml then acetonitrile (68 ml) was added and the mixture was stirred at room temperature for 17.5 h. The product was isolated by filtration under nitrogen, washed with acetonitrile (20ml) and dried at 40°C in a vacuum oven for 24 h to obtain 2.18 g (ca. 64%) of fluvastatin sodium crystal Form XIV (Form B: non-detectable).

Example 15

A solution of Fluvastatin sodium that was prepared as described in Example 12 (42ml) was concentrated until the water volume was ca. 0.8 ml then acetone (68 ml) was added and the mixture was stirred at room temperature for 24.5 h. The product was isolated by filtration under nitrogen, washed with acetone (20ml) and dried at 40°C in a vacuum oven for 22 h to obtain 2.65 g (ca. 78%) of fluvastatin sodium crystal Form XIV.

Example 16

Acetonitrile (30ml) and brine (15 ml) added to solution of Fluvastatin sodium that was prepared as described in example 12 (30ml). The phases were separated and the organic phase was extracted with brine (15ml), then acetonitrile (30 ml) was added to the organic phase which was stirred at room temperature over night. The product was isolated
by filtration under nitrogen, washed with acetonitrile (30 ml) and dried at 40°C in a vacuum oven for 24 h to obtain 1.99 g (ca. 80%) of fluvastatin sodium crystal Form XIV (+NaCl residue).

**Example 17**

EtOAc (32 ml) and brine (16 ml) added to solution of Fluvastatin sodium that was prepared as described in Example 12 (32 ml contains ca. 3 g fluvastatin sodium) The phases were separated and the organic phase was extracted with brine (10 ml), then EtOAc (32 ml) was added to the organic phase which was stirred at room temperature over night. The product was isolated by filtration under nitrogen, washed with EtOAc (90 ml) and dried at 40°C in a vacuum oven for 24 h to obtain 2.43 g (ca. 80%) of fluvastatin sodium crystal Form XIV (+NaCl residue).

**Example 18**

A 250 ml round bottom flask was loaded with Fluvastatin tert-butyl ester (3.0 g, 6.4 mmole), water (27 ml), THF (7.5 ml) and NaOH (0.29 g). The mixture was stirred for 1.5 h then THF (2.5 ml) was added. After another 0.5 h THF (2.5 ml) was added again and the solution became clear. The solution was stirred for another 5 h then extracted with EtOAc (2 x 20 ml). The clear solution was divided to 2 parts.

**Example 19**

A solution of Fluvastatin sodium that was prepared as described in Example 18 was concentrated until the weight was 1.51 g then acetonitrile (30 ml) was added and the mixture was stirred at room temperature over night. The product was isolated by filtration under nitrogen flow, washed with acetonitrile and dried at 40°C in a vacuum oven for 24 h to obtain 0.56 g (ca. 40%) of fluvastatin sodium crystal Form XIV.

**Example 20**

A solution of Fluvastatin sodium that was prepared as described in Example 18 was concentrated until the weight was 1.5 g then acetone (30 ml) was added and the mixture was stirred at room temperature over night. The product was isolated by filtration under nitrogen flow, washed with acetone and dried at 40°C in a vacuum oven for 24 h to obtain 1 g (ca. 72%) of fluvastatin sodium crystal Form XIV.

**Preparation of Fluvastatin Sodium Crystal Form LXXIII**

**Example 21**

In a 50 ml flask were placed fluvastatin sodium crystal Form VI (1.33 g) and water (2.3 ml). The mixture was heated to reflux for dissolving and acetonitrile (23 ml) was added. After 2 h the mixture was cooled to room temperature and stirred over night. The product was isolated by filtration under nitrogen, washed with acetonitrile (20 ml) and
dried at 50°C in a vacuum oven for 24 h to obtain 1.09 g (82%) of fluvastatin sodium crystal Form LXXIII (Form B: non-detectable).

Example 22

A 100 ml round bottom flask was loaded with fluvastatin methyl ester (5.0 g, 11.8 mmole), water (15 ml), EtOH (25 ml) and NaOH (0.49 g). The mixture became clear and was stirred for 4.5 h. The EtOH was evaporated, water (completing to 10 vol.) was added and extracted with ethyl acetate (2x20 ml). The aqueous phase was evaporated, then acetonitrile (70 ml) was added and the mixture was stirred at room temperature overnight. The product was isolated by filtration under nitrogen flow, washed with acetonitrile (20 ml) and dried at 40°C in a vacuum oven for 24 h to obtain 3.31 g (65%) of fluvastatin sodium crystal Form LXXIII.

Example 23

A 100 ml round bottom flask was loaded with fluvastatin sodium (crystal form XIV that contains NaCl residues, 1.5 g), propan-2-ol (25 ml) and water (2.5 ml). The mixture was heated to reflux for 3.3 h (became clear) then cooled to room temperature and stirred for 22 h. The product was isolated by filtration under nitrogen flow, washed with propan-2-ol (20 ml) and dried at 40°C in a vacuum oven for 22 h to obtain 0.75 g (ca. 50%) of fluvastatin sodium crystal Form LXXIII.

Example 24

A 1 liter reactor was loaded with Fluvastatin tert-butyl ester (70 g, 0.15 mole), water (576 ml), THF (280 ml) and NaOH (6 g). After 2 h THF (35 ml) was added and the mixture was stirred for another 9.5 h. The solution was extracted with ethyl acetate (2x200 ml). The aqueous phase was distilled and acetonitrile (1050 ml) was added and the mixture was stirred at room temperature overnight. The product was isolated by filtration under nitrogen flow, washed with acetonitrile and dried at 40°C in a vacuum oven for 24 h to obtain 50.4 g (77.6%) of fluvastatin sodium crystal Form LXXIII (water content: 5.9% wt.% by KF, LOD by TGA 6.0 wt.%).

Example 25

A 100 ml round bottom flask was loaded with fluvastatin methyl ester (5 g, 11.7 mmole), water (45 ml), THF (12.5 ml) and NaOH (0.48 g). The solution was stirred for 1.5 h then extracted with ethyl acetate (20 ml) and filtered. The aqueous phase was distilled and acetonitrile (100 ml) was added and the mixture was stirred at room temperature overnight. The product was isolated by filtration under nitrogen flow, washed with acetonitrile (15 ml) and dried at 50°C in a vacuum oven for 24 h to obtain 4.16 g (82%) of fluvastatin sodium crystal Form LXXIII.

Example 26
A suspension of fluvastatin sodium crystal form B (30.0 g) in a mixture of propan-2-ol (501 ml) and water (51 ml) was heated to reflux temperature for 16 h. The suspension was then cooled to room temperature. A small amount of solid was isolated by filtration to give fluvastatin sodium crystal Form LXXIV (PXRD pattern with peaks at 4.0, 12.8, 19.0, 19.9 and 25.8 ±0.2 degrees two-theta) (4.7 g) after drying at 50°C in a vacuum oven for 21.5 h. The mother-liquid were allowed to stand at room temperature for 2 months. Then, the precipitate was filtered under nitrogen flow, washed with propan-2-ol (2x25 ml) and dried at 50°C in a vacuum oven for 24 h to give 16.2 g of fluvastatin sodium crystal Form LXXIII.

**Example 27**

A 100 ml round bottom flask was loaded with fluvastatin methyl ester (5.0 g, 11.8 mmole), water (15 ml), EtOH (25 ml) and NaOH (0.49 g). The mixture became clear and was stirred for 4.5 h. The EtOH was evaporated, water (completing to 10 vol.) was added and extracted with EtOAc (2x20 ml). The aqueous phase was evaporated, then acetonitrile (70 ml) was added and the mixture was stirred at room temperature over night. The product was isolated by filtration under nitrogen flow, washed with acetonitrile (20 ml) and dried at 40°C in a vacuum oven for 24 h to obtain 3.31 g (65%) of fluvastatin sodium crystal Form LXXIII.

**Example 28**

A 100 ml round bottom flask was loaded with fluvastatin tert-butyl ester (4 g, 8.57 mmole) and MeOH (24 ml). NaOH (0.35g) in water (2 ml) was added and the mixture was stirred at 35°C for 1 h, then water (10 ml) was added. After 24 h, the MeOH was evaporated, water (32 ml) was added extracted twice with EtOAc. The aqueous layer was evaporated until it contained ca. 4ml water. Then acetonitrile (60 ml) was added and the mixture was stirred at room temperature overnight. The product was isolated by filtration under nitrogen flow, washed with acetonitrile and dried at 40°C in a vacuum oven for 20 h to obtain 3.0 g (81%) of fluvastatin sodium crystal form LXXIII.

**Preparation of Fluvastatin Sodium Crystal Form LXXIX**

**Example 29**

A 250 ml round bottom flask was loaded with Fluvastatin tert-butyl ester (8.0g, 17mmole), water (64ml), EtOH (160ml) and NaOH (0.7g). The mixture was stirred for 43 h then the EtOH was evaporated. Water (53ml) was added and the mixture was extracted with EtOAc (2x35ml). The aqueous solution was evaporated to obtain 18g and ACN (120ml) was added. The solution was stirred at room temperature over night. The product was isolated by filtration under nitrogen, washed with ACN (20ml) and dried at 40°C in a vacuum oven for 24 h to obtain 4.43 g (60%) of fluvastatin sodium crystal form LXXIX.
Example 30
A 100 ml round bottom flask was loaded with fluvasatin tert-butyl ester (2.0 g, 4.28 mmole), EtOH (20 ml) and NaOH (0.18 g). The mixture was heated to 50°C and stirred for 2.25 h then cooled to room temperature and the EtOH was evaporated. The volume of the water was completed to 8 vol. and the mixture was extracted with EtOAc (2 x 20 ml). The aqueous solution was evaporated to obtain 4.22 g and ACN (30 ml) was added. The solution was stirred at room temperature over the weekend. The product was isolated by filtration under nitrogen, washed with ACN (20 ml) and dried at 40°C in a vacuum oven for 24 h to obtain 1.15 g (62%) of fluvasatin sodium crystal form LXXIX.

Preparation of Fluvasatin Sodium Crystal Form LXXX
Example 31
A 250 ml round bottom flask was loaded with fluvasatin tert-butyl ester (4.0 g, 8.56 mmole), NaOH (0.35 g), water (48 ml) and EtOH (120 ml) which were added gradually till clear solution was obtained. The mixture was stirred for 2.5 h then the EtOH was evaporated. The volume of the water was completed to 8 vol. and the mixture was extracted with EtOAc (2 x 30 ml). The aqueous solution was evaporated to obtain 6.07 g and ACN (60 ml) was added. The solution was stirred at room temperature over night. The product was isolated by filtration under nitrogen, washed with ACN (20 ml) and dried at 40°C in a vacuum oven for 24 h to obtain 2.86 g (77.1%) of fluvasatin sodium crystal form LXXX.

Preparation of Fluvasatin Sodium Crystal Form XIV, having a peak at 12.4±0.2 degrees two-theta in the XRD pattern
Example 32
A 100 ml round bottom flask was loaded with fluvasatin tert-butyl ester (4.0 g, 8.56 mmole), MeOH (24 ml) and NaOH (0.35 g) in water (2 ml). The mixture was heated to 35°C. After 2 h water (10 ml) was added and the mixture was stirred for another 4.5 h then the MeOH was evaporated. The volume of the water was completed to 8 vol. and the mixture was extracted with EtOAc (24 ml). The aqueous solution was evaporated to contain ca. 1 vol. water and ACN (60 ml) was added. The solution was stirred at room temperature over night. The product was isolated by filtration under nitrogen, washed with ACN (15 ml) and dried at 40°C in a vacuum oven for 24 h to obtain 3.18 g (85.7%) of fluvasatin sodium crystal form XIV, having a peak at 12.4±0.2 degrees two-theta in the XRD pattern
Example 33
A 100 ml round bottom flask was loaded with fluvasatin tert-butyl ester (4.0 g, 8.56 mmole), MeOH (24 ml) and NaOH (0.31 g) in water (2 ml). The mixture was heated...
to 350°C and stirred for 4.5 h then water (10 mL) was added and the MeOH was evaporated. The volume of the water was completed to 8 vol. and the mixture was extracted with EtOAc (25 mL). The aqueous solution was evaporated to contain ca. 1 vol. water and ACN (60 mL) was added. The solution was stirred at room temperature over night. The product was isolated by filtration under nitrogen, washed with ACN and dried at 40°C in a vacuum oven for 24 h to obtain 1.66 g (28.6%) of fluvastatin sodium crystal form XIV, having a peak at 12.4±0.2 degrees two-theta in the XRD pattern.

Preparation of Fluvastatin Sodium Crystal Form LXXXVII

Example 34

Into a 1 L reactor equipped with mechanical stirrer and thermometer, 40 g of fluvastatin diol tert-butyl ester and 240 mL MeOH were charged. 3.54 g of NaOH dissolved in 20 mL water were added and the mixture was heated to 35°C. After 1 hour the solution became clear and 100 mL water were added. The reaction solution was maintained at 35°C under mixing during 4 hours. The MeOH was distilled by vacuum at 40°C and water (230 mL) was added in order to complete the volume to 8 volumes vs. 1 gr of fluvastatin diol tert-butyl ester. The aqueous mixture was extracted with 240 mL MTBE. After vacuum filtration the water was distilled by vacuum at 60°C. ACN (120 mL) was added at room temperature is with vigorously stirring in order to get maximum dissolving. The amount of water in the clear solution was determined by Karl Fisher method and calculated to be 1.6 vol then 680 mL of ACN were added. The reaction solution was maintained at 25°C under mixing over night. The product was isolated by vacuum filtration under N₂ flow, washed with ACN (100 mL) (crystal Form LXXXVII), dried in vacuum oven at 40°C for 25 hours to obtain 29.2 g (78.8%) fluvastatin sodium crystal Form XIV.

Example 35

Fluvastatin diol tert-butyl ester (80 g), methanol (480 mL), 47% NaOH solution (14.87 g) and water (32.1 mL) were added into a stirred reactor and heated to 35°C. When the solution became clear (~1 hr), additional water (80 mL) was added. The solution was stirred at 35°C for additional 2 hours. Methanol was distilled by vacuum distillation at 60 mmHg and a jacket temp of 40°C. When distillation ended, ACN (240 mL) and water (54 mL) were added until dissolution occurred. ACN (680 mL) was added to half of the solution (193 g) at 25°C. The product precipitated during the ACN addition. The mixture was stirred at 25°C for additional 12 hours, then filtered with vacuum and the wet product was washed with ACN (120 mL). XRD detection for the wet product is Form LXXXVII (Form B: non-detectable). The wet product was dried in a vacuum oven at 40°C for 12-15 hours. XRD detection for the dry product was Form XIV.

Example 36
Fluvastatin diol tert-butyl ester (40 g), methanol (240 ml), 47% NaOH solution (7.44 g) and water (16.1 ml) were added into a stirred reactor and heated to 35°C. When the solution became clear (~1 hr) additional water (40 ml) was added. The solution was stirred at 35°C for additional 2 hours. Methanol was distilled by vacuum distillation at 60 mmHg and a jacket temp of 40°C. When distillation ended, ACN (120 ml) and water (30 ml) were added until dissolution occurred. ACN (680 ml) was again added to the solution at 25°C. The product precipitated during the ACN addition. The mixture was stirred at 25°C for additional 12 hours, then filtered with vacuum and the wet product was washed with ACN (120 ml). XRD detection for the wet product was Form LXXXVII. The wet product was dried in a vacuum oven at 40°C for 12-15 hours. XRD detection for the dry product was Form XIV.

**Example 37**

500 g of Fluvastatin diol tert-butyl ester and 3000 ml of methanol were added to a 10 liter reactor and stirred at room temperature. A solution of 45.5 g of 100% NaOH and 250 ml water was added. The mixture was heated to 35-36 deg. by setting the jacket temperature to 40°C. When the mixture became a clear solution (~60 min). According to KF result, the solution contained 2.7 vol. of water (per g Fluvastatin diol tert-butyl ester)." 1250 ml of water were added. End of reaction was determined by HPLC after 90 min. Methanol was distilled at 40°C in jacket and <60 mmHg vacuum. 2680 ml water were added and the mixture was cooled to 5°C and stirred overnight. In the morning, 3000 ml of MTBE were added. The mixture was heated to 25°C and stirred for 20 min. Stirring was stopped for phase separation. The aqueous phase was distilled for water removal at 60°C and <60 mmHg vacuum. 1500 ml of ACN were added at 25°C and the mixture became a clear solution. 1500 ml of ACN were added to the solution and the mixture was stirred at 25°C overnight (~16 h). Precipitation occurred during ACN addition. The product was filtered with suction and washed with 1500 ml of ACN. 610 g of wet product were obtained (detected to be form 87 by XRD, RL-4197/3 sample). Wet product was dried in a vacuum oven at 40°C for 24 h. 380 g of dry product was obtained (detected to be form XIV by XRD, RL-4197/4 sample).

**Preparation of Fluvastatin Sodium Crystal Form B**

**Example 38**

Fluvastatin methyl ester (3.0 g) was added to a solution of NaOH (1 eq.) in water (0.75 ml) and methanol (7.5 ml). The mixture was stirred at reflux temperature for 2 h. After this time the raw material was not observed by HPLC. MTBE (58 ml) was dripped into the solution over 2 h. The solution was cooled slowly to room temperature and was stirred overnight. The product was isolated by filtration under nitrogen, washed with
MTBE (50 ml) and dried at 50°C in a vacuum oven for 24 h to obtain 2.78 g (91.3%) of fluvastatin sodium Form B.

Preparation of Fluvastatin Sodium Crystal Form IV

Example 39

Fluvastatin sodium (3.0 g) was dissolved in tetrahydrofuran (THF) (50 ml) at reflux temperature. Chloroform (50 ml) was added dropwise at reflux temperature and the resulting mixture was stirred at this temperature for 40 minutes. A precipitate was obtained during reflux. Then, the mixture was cooled to room temperature. The product was isolated by filtration under nitrogen, washed with Chloroform (2x20 ml) and dried at 50°C in a vacuum oven for 19 h to obtain 2.7 g (89%) of fluvastatin sodium crystal Form IV.
The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows:

1. A crystalline form of fluvastatin sodium (Form LXXIX) characterized by a PXRD pattern with peaks at 3.9, 11.7, 15.8, 17.8, 21.8±0.2 degrees two-theta.

2. The crystalline form of claim 1 further characterized by peaks at 3.4, 13.0, 18.3, 19.5, 22.6±0.2 degrees two-theta.

3. The crystalline form of claim 1 wherein the crystalline form is characterized by a PXRD pattern as depicted in Figure 6.

4. The crystalline form of claim 1 of which no more than about 5% transforms to Form B under exposure to relative humidities of about 0 to about 100% for at least 8 days.

5. The crystalline form of claim 1 having a water content of about 3 to about 19%.

6. A process for preparing the crystalline fluvastatin sodium form of any one of claims 1 to 5 comprising:
   a) hydrolyzing a lower alkyl ester of fluvastatin with a sodium base catalyst in a mixture of water and ethanol;
   b) evaporating a portion of the ethanol and water mixture;
   c) contacting the remaining portion of the mixture with a water-immiscible extraction solvent;
   d) evaporating the remaining portion of the mixture to leave a residue;
   e) contacting the residue with acetonitrile; and
   f) recovering the crystalline fluvastatin sodium form.

7. A pharmaceutical composition comprising an effective amount of a crystalline fluvastatin sodium Form LXXIX having a PXRD pattern with peaks at 3.9, 11.7, 15.8, 17.8, 21.8±0.2 degrees two-theta, and a pharmaceutically acceptable excipient.

8. A pharmaceutical dosage form prepared from the pharmaceutical composition of claim 7.
9. Use of the pharmaceutical composition of claim 7 to treat a patient suffering from hypercholesterolemia or hyperlipidemia.
FIG. 2

INTEGRAL -130.71 mJ
NORMALIZED -38.56 Jg⁻¹
PEAK 63.07 °C
LEFT LIMIT 35.72 °C
RIGHT LIMIT 86.36 °C

INTEGRAL -266.72 mJ
NORMALIZED -78.68 Jg⁻¹
PEAK 113.90 °C
LEFT LIMIT 90.14 °C
RIGHT LIMIT 141.49 °C
FIG. 3a

FLUVASTATIN, NO. FORM XIV
DRIFT: 16 SCANS, 4.0 RESOLUTION

3330.4
2994.3
2937.5
2880.0
1887.6
1768.8
2252.2
1586.3
1535.3
1644.7

SUBSTITUTE SHEET (RULE 26)